Fakultna Nemocnica S Poliklinikou J. A. Reimana Presov — Clinical Trial Site

18 Registered trials

4 Currently recruiting

Organisation

Fakultna Nemocnica S Poliklinikou J. A. Reimana Presov

Location

Presov, Slovakia

Identifier

ORG-100045702

Address

Jana Holleho 5898/14, 080 01, Slovakia

Departments

#2731:Dermatovenerologické oddelenie
Cardiocenter
Clinical Oncology department
Department of Clinical Oncology
dermatologia
Dermatology Department
Dermatovenerology
Kardiologicka ambulancia
Neurologická klinika
Neurologické oddelenie
Oddelenie dermatovenerologie
Oddelenie klinickej onkologie
Oddelenie neurologie
Outpatient care of clinical oncology

Clinical trials at this site (18)

Search interface

A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo… Recruiting

2025-522093-36-00 Cancer cachexia 10 2026-05-20
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-11-28
Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting

2023-508956-20-00 Hidradenitis suppurativa 5 2020-03-12
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended

2023-505061-82-01 Alopecia Areata 5 2024-06-17
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
Phase 3, Randomized, Open-Label Study of ARV-471 (PF-07850327) Plus Palbociclib vs Letrozole Plus Palbociclib in Participants With ER(+)/HER… Ended

2022-500545-24-00 ER + /HER 2 - Advanced Breast Cancer 5 2023-10-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Atopic Dermatitis 5 2019-01-02
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended

2024-518364-12-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-05-09
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended

2024-512646-42-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2023-06-27
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18